{"gene":"CD72","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":1991,"finding":"CD72 (Lyb-2) on B cells is the ligand for CD5 on T cells. Purified biotinylated CD5 protein specifically bound CD72-expressing cells; binding was blocked by anti-CD72 antibodies; non-B cells (mouse L-cell fibroblasts and human Jurkat T cells) transfected with human CD72 cDNA acquired the ability to bind CD5-biotin conjugate.","method":"Biotin-labeled CD5 probe binding assay, antibody blocking, transfection of CD72 cDNA into non-B cells","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct binding assay with purified protein, gain-of-function transfection, blocking antibody confirmation, independently replicated in mouse system (PMID:1371783)","pmids":["1711157","1371783"],"is_preprint":false},{"year":2000,"finding":"CD72 is the receptor for the class IV semaphorin CD100/Sema4D on lymphocytes (Kd ≈ 3×10⁻⁷ M). CD100 stimulation induces tyrosine dephosphorylation of CD72 and dissociation of SHP-1 from CD72, thereby switching off CD72-mediated negative signaling in B cells.","method":"Expression cloning, binding affinity measurements, tyrosine phosphorylation assay, co-immunoprecipitation of SHP-1 from CD72","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — expression cloning identification plus biochemical dephosphorylation and SHP-1 dissociation assays, replicated with human proteins (PMID:12882840) and in vivo (PMID:16113236)","pmids":["11114375","12882840","16113236"],"is_preprint":false},{"year":1998,"finding":"The cytoplasmic domain of CD72 carries an ITIM that, upon tyrosine phosphorylation, recruits the tyrosine phosphatase SHP-1. BCR cross-linking enhances tyrosine phosphorylation of CD72 and its association with SHP-1 in B-cell line WEHI-231.","method":"In vitro ITIM phosphopeptide pull-down, co-immunoprecipitation from BCR-stimulated B cells","journal":"Journal of Immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro ITIM-SHP-1 interaction plus BCR-stimulated co-IP in cell line; independently confirmed by multiple labs (PMID:9740800, PMID:10549631)","pmids":["9590210","9740800"],"is_preprint":false},{"year":1998,"finding":"CD72 is an in vivo substrate of SHP-1 in B cells. Tyrosine phosphorylation of CD72 strongly correlates with BCR-induced growth arrest/apoptosis. The binding sites for SHP-1 and the adaptor Grb2 on CD72 were defined. Preligation of CD72 attenuated BCR-induced growth arrest/death signals in B cells.","method":"Co-immunoprecipitation from primary B cells and B-cell lines, correlation of CD72 phosphorylation with apoptosis, CD72 preligation rescue assay","journal":"Current Biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo substrate identification with defined binding sites, multiple orthogonal methods (co-IP, functional rescue), confirmed in primary B cells","pmids":["9740800"],"is_preprint":false},{"year":1999,"finding":"CD72-deficient mice show: (1) reduced mature recirculating B cells and accumulation of pre-B cells in bone marrow; (2) fewer mature B-2 cells and more B-1 cells in periphery; (3) hyperproliferative B cells and enhanced Ca²⁺ response following IgM cross-linking. CD72 is thus a nonredundant regulator of B cell development and a negative regulator of B cell activation.","method":"Gene knockout mouse model, flow cytometry of B cell subsets, proliferation assays, intracellular Ca²⁺ measurement","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with multiple defined cellular phenotypes (development and activation), orthogonal readouts (Ca²⁺, proliferation, subset counting)","pmids":["10549631"],"is_preprint":false},{"year":2000,"finding":"CD72 negatively regulates BCR signaling through its ITIM motif. Expression of CD72 in B lymphoma K46 cells down-modulates BCR-induced ERK activation and Ca²⁺ mobilization; this inhibition requires the intact ITIM, as an ITIM-mutated CD72 did not reduce ERK activation. Co-ligation of CD72 with BCR in normal spleen B cells also reduced BCR-mediated ERK activation.","method":"Transfection of wild-type vs. ITIM-mutant CD72, ERK activation assay, Ca²⁺ mobilization assay, co-ligation experiments in primary B cells","journal":"Journal of Immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — active-site (ITIM) mutagenesis combined with functional readouts (ERK, Ca²⁺) in cell lines and primary cells","pmids":["10640734"],"is_preprint":false},{"year":1998,"finding":"CD72 ligation activates Src-family kinases Lyn and Blk, and the Tec-family kinase Btk, but not Syk. Btk is required for CD72-induced B cell proliferation, as B cells from xid (Btk-deficient) mice are unresponsive to CD72-induced proliferation. CD72-mediated PLC-γ2 tyrosine phosphorylation occurs independently of Syk activation.","method":"Kinase activity assays after CD72 ligation, xid (Btk-deficient) mouse B cells, PLC-γ2 phosphorylation assay","journal":"Journal of Immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — defined kinase activation hierarchy with genetic (xid) validation, multiple orthogonal biochemical assays","pmids":["9531290"],"is_preprint":false},{"year":1998,"finding":"CD72 ligation recruits CD19 and activates CD19-associated PI 3-kinase. CD72 ligation induces CD19 tyrosine phosphorylation and a transient physical association between CD19 and CD72. PI 3-K inhibitors block CD72-stimulated B cell proliferation. CD72 signaling is Syk-independent even when co-cross-linked with CD19.","method":"PI 3-K inhibitor assays, CD19 phosphorylation, co-immunoprecipitation of CD72 and CD19","journal":"European Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP and functional inhibition, single lab, two orthogonal approaches","pmids":["9808169"],"is_preprint":false},{"year":2000,"finding":"The adaptor protein BLNK is associated with the CD72/SHP-1/Grb2 complex via the SH3 domain(s) of Grb2 in WEHI-231 cells after mIgM engagement, forming a CD72/SHP-1/Grb2/BLNK complex.","method":"Co-immunoprecipitation from BCR-stimulated WEHI-231 cells","journal":"European Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP demonstrating quaternary complex, single lab, confirmed in normal primary B cells","pmids":["10820378"],"is_preprint":false},{"year":2001,"finding":"CD72 ligation induces ERK and JNK (but not p38) MAPK activation via PKC-dependent pathways, and CD72 signaling compensates for defective BCR signaling in Btk-deficient (xid) B cells, partially restoring proliferation to anti-IgM. This establishes CD72 as capable of inducing BCR-independent positive signaling.","method":"MAPK activation assays, PKC inhibitors, xid mouse B cells, proliferation assays","journal":"Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic (xid) and pharmacological validation, single lab, multiple kinase pathway readouts","pmids":["11466342"],"is_preprint":false},{"year":2005,"finding":"CD72 ITIM1 (which binds SHP-1) delivers a strong negative signal that is attenuated by ITIM2 (which binds Grb2). ITIM1-only mutants (Y7/F) showed the least sensitivity to growth inhibition, double ITIM mutants (Y7,39/F) were also less sensitive, and Y39/F (ITIM2 mutant) cells were unrecoverable, suggesting ITIM2/Grb2 acts as a moderator of ITIM1/SHP-1 negative signaling.","method":"ITIM tyrosine-to-phenylalanine mutagenesis in retroviral vectors, BCR cross-linking growth inhibition assay","journal":"European Journal of Immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — active-site mutagenesis (multiple ITIM point mutants) with defined functional readout, single lab","pmids":["15816000"],"is_preprint":false},{"year":2005,"finding":"CD100 regulates BCR signal sensitivity by preventing constitutive association of CD72 with the BCR. In CD100-deficient mice, BCR signals are suppressed due to constitutive SHP-1 association with CD72, causing B-cell hyporesponsiveness and, with aging, accumulation of marginal zone B cells, elevated autoantibodies, and autoimmunity.","method":"CD100-knockout mice, BCR co-immunoprecipitation with CD72, B-cell functional assays, flow cytometry, autoantibody measurement","journal":"International Immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO combined with biochemical co-IP demonstrating CD72-BCR association, multiple in vivo phenotypic readouts","pmids":["16113236"],"is_preprint":false},{"year":2008,"finding":"In anergic B cells, CD72 down-regulates BCR signaling by limiting antigen-induced Ca²⁺ elevation and activation of NFATc1, NF-κB, MAPK, and Akt. CD72 is physically associated with and regulates the molecular adaptor Cbl-b in anergic B cells. CD72-deficient anergic B cells inappropriately proliferate and survive in response to self antigen, and aged CD72-deficient mice develop lupus-like autoimmune disease.","method":"CD72-knockout mice crossed with HEL-specific BCR transgenic mice, Ca²⁺ flux measurements, NF-κB/NFAT/MAPK/Akt signaling assays, co-immunoprecipitation of Cbl-b","journal":"Arthritis and Rheumatism","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO in antigen-specific transgenic system, multiple signaling pathway readouts, co-IP of novel Cbl-b interaction","pmids":["18821699"],"is_preprint":false},{"year":2016,"finding":"CD72 binds the RNA-containing lupus self-antigen Sm/RNP through its extracellular C-type lectin-like domain (CTLD) and specifically inhibits B cell responses to Sm/RNP. X-ray crystallographic analysis of the lupus-susceptible CD72c allele CTLD reveals considerable alteration in charge at the putative ligand-binding site, which correlates with weaker Sm/RNP binding by CD72c compared with the lupus-resistant CD72a allele.","method":"CTLD-Sm/RNP binding assay, TLR7-dependent B cell response inhibition assay, x-ray crystallography of CD72c CTLD","journal":"Journal of Experimental Medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with direct binding assay and functional B cell inhibition assay demonstrating allele-specific mechanism","pmids":["27810925"],"is_preprint":false},{"year":1989,"finding":"CD72 (Lyb-2) is a type II transmembrane protein with inverted membrane orientation (C-terminus extracellular), lacking an N-terminal signal peptide, and is homologous to the asialoglycoprotein receptor and CD23, defining a gene superfamily of C-type lectin-like receptors with inverted orientation.","method":"cDNA sequencing, sequence comparison, predicted protein topology analysis","journal":"Proceedings of the National Academy of Sciences USA","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct cDNA sequencing with structural prediction validated by expression, founding structural characterization replicated across species","pmids":["2645579"],"is_preprint":false},{"year":2010,"finding":"CD72 is expressed on human mast cells. Ligation of CD72 (by agonistic antibody or recombinant CD100) induces CD72 tyrosine phosphorylation and increased association with SHP-1, resulting in inhibition of KIT-induced Src family kinase and ERK1/2 phosphorylation. This reduces KIT-mediated mast cell proliferation, chemotaxis, and chemokine production.","method":"Flow cytometry for CD72 expression, co-immunoprecipitation of SHP-1 with CD72, phosphorylation assays, proliferation and chemotaxis assays","journal":"Journal of Immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — co-IP showing SHP-1 recruitment, multiple functional readouts (proliferation, chemotaxis, cytokine), two activating stimuli tested","pmids":["20100931"],"is_preprint":false},{"year":2009,"finding":"CD72 is expressed on mouse NK cells and inhibits IFN-γ production but not cytotoxicity. Ectopic expression of CD72 in the NK-cell line KY2 inhibits cytokine-induced IFN-γ production; this inhibitory effect is diminished by mutations in the intracellular inhibitory motifs or replacement of the extracellular domain.","method":"Ectopic CD72 expression in NK cell line, IFN-γ production assay, intracellular domain mutants, cytotoxicity assay","journal":"European Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function expression plus domain mutants in NK cell line, single lab, two functional readouts","pmids":["19197938"],"is_preprint":false},{"year":1998,"finding":"PU.1/Spi-1 binds the CD72 promoter (footprint FP I) and is essential for B cell-specific promoter activity. Mutation of the PU.1 binding site abolishes B cell-specific CD72 promoter activity in transient reporter assays.","method":"DNase I footprinting, EMSA, reporter gene deletion and mutation analysis in B cells vs. non-B cells","journal":"Journal of Immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — footprinting, EMSA, and mutagenesis of transcription factor binding site demonstrating necessity of PU.1 for promoter activity","pmids":["9498769"],"is_preprint":false},{"year":2006,"finding":"CD72 loss-of-function in mature B lymphocytes (CD72-deficient HEL BCR transgenic mice) down-regulates BCR-induced NF-AT, NF-κB, ERK, JNK, p38-MAPK, and PI3K/Akt signaling pathways. CD72 ligation (mimicking CD100 binding) augments Ca²⁺ flux, IκBα activation, and ERK activity upon antigen stimulation, and CD72 promotes cell cycle arrest and apoptosis after antigen stimulation.","method":"CD72-knockout BCR-transgenic mice, luciferase reporter assays for NF-AT/NF-κB, MAPK/PI3K-Akt signaling assays, Ca²⁺ flux measurement, cell cycle and apoptosis analysis","journal":"Journal of Immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO in antigen-specific BCR transgenic system, comprehensive signaling pathway mapping with multiple orthogonal methods","pmids":["16621999"],"is_preprint":false},{"year":2004,"finding":"CD72 loss-of-function in B cells (CD72-deficient BAL-17 cells) impairs BCR-mediated phosphorylation of CD19, Btk, Vav, and PLC-γ2, and CD19-PI3K association. Ca²⁺ release from intracellular stores is intact but extracellular Ca²⁺ influx is severely impaired. BCR-evoked ERK and JNK activation and growth inhibition are also blocked; these effects are reversed by re-expression of CD72.","method":"CD72-deficient B-cell lines generated from BAL-17 cells, phosphorylation assays, Ca²⁺ influx measurement, re-expression rescue experiment","journal":"International Immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function cell line with rescue by re-expression, comprehensive signaling pathway analysis, multiple orthogonal readouts","pmids":["15148289"],"is_preprint":false},{"year":2005,"finding":"CD72 cross-linking in human naive B cells suppresses differentiation into plasma cells by down-regulating X-box binding protein 1 (XBP-1) and CD27 expression, without affecting PRDI-BF1. This inhibition is dependent on the stimulation context (SAC+IL-2 but not CD40 signaling or CpG).","method":"CD72 cross-linking, XBP-1 and PRDI-BF1 expression analysis, Ig synthesis measurement, CD27 flow cytometry","journal":"European Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined molecular target (XBP-1) with context-dependent functional readouts, single lab","pmids":["16047337"],"is_preprint":false},{"year":1987,"finding":"Ligation of Lyb-2 (CD72) via monoclonal antibody induces phosphatidylinositol (PI) hydrolysis in murine B cells in a dose-dependent, allele-specific manner. This PI response is distinct from that induced by BSF-1 (IL-4), which does not induce a PI response and does not competitively inhibit anti-Lyb-2-induced PI turnover, indicating CD72 uses a different signaling pathway from BSF-1.","method":"PI metabolism assay in B cells, dose-response and allele-specificity controls, BSF-1 competition assay","journal":"Cellular Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct biochemical assay (PI hydrolysis) with allele-specificity and competition controls, single lab","pmids":["3499987"],"is_preprint":false},{"year":2004,"finding":"CD72 stimulation of immature B cells (WEHIdelta) prevents BCR-induced apoptosis by sustaining c-Myc expression, inhibiting p27(Kip1) accumulation, and preventing NF-κB suppression after mIgM cross-linking.","method":"CD72 pre-ligation followed by mIgM cross-linking, c-Myc protein expression, p27(Kip1) level measurement, NF-κB activity assay","journal":"Microbiology and Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined molecular pathway (c-Myc, p27Kip1, NF-κB) with CD72 pre-ligation rescue paradigm, single lab","pmids":["14734859"],"is_preprint":false},{"year":2022,"finding":"Semaphorin3A (Sema3A) binds CD72 on B cells as a novel ligand, independent of neuropilin-1. Sema3A binding induces CD72 tyrosine phosphorylation and association of CD72 with SHP-1 and SHP-2. This inhibits STAT-4 and HDAC-1 phosphorylation and induces p38-MAPK and PKC-theta phosphorylation in B cells.","method":"Co-immunoprecipitation of Sema3A-CD72 interaction, phosphorylation assays (CD72 tyrosine, SHP-1/2, STAT-4, HDAC-1, p38-MAPK, PKC-theta), neuropilin-1 independence validation, primary B cells from SLE patients","journal":"Journal of Autoimmunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP identifying new ligand plus defined signaling pathway, validated in primary B cells, single lab","pmids":["36470209"],"is_preprint":false},{"year":2012,"finding":"The alternatively spliced human CD72 isoform lacking exon 8 (CD72Δex8) accumulates in the endoplasmic reticulum and fails to reach the cell surface and fails to regulate BCR signaling, whereas full-length CD72 (CD72fl) is efficiently transported to the cell surface and inhibits BCR signaling.","method":"Transfection of CD72fl and CD72Δex8 into mouse cell lines, subcellular fractionation/localization, BCR signaling inhibition assay","journal":"BMC Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiment combined with functional BCR signaling assay, single lab","pmids":["23268649"],"is_preprint":false},{"year":2013,"finding":"CD72 ligation in the AML cell line Kasumi-1 (expressing mutant KIT) suppresses proliferation and enhances cell death (caspase-3 cleavage), associated with CD72 phosphorylation, CD72-SHP-1 complex formation, and dephosphorylation of Src family kinases and JNK.","method":"CD72 ligation with agonistic antibody and recombinant CD100, proliferation assay, caspase-3 cleavage, co-immunoprecipitation of SHP-1, Src and JNK phosphorylation assays","journal":"Scientific Reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic co-IP plus functional readouts in a defined cell line, single lab","pmids":["24713856"],"is_preprint":false},{"year":2014,"finding":"In mouse mast cells, CD72 ligation inhibits KIT-mediated growth, IL-6 production, and chemotaxis via Cbl-b phosphorylation and downregulation of KIT and FcεRIα surface expression. Unlike human mast cells, CD72 in mouse mast cells does not signal through SHP-1 for these effects. IgE-triggered degranulation is also suppressed by CD72 ligation in mouse (but not human) mast cells.","method":"CD72 ligation in mouse bone marrow-derived mast cells, Cbl-b phosphorylation assay, KIT and FcεRIα surface expression by flow cytometry, degranulation assay, comparison to human mast cell mechanism","journal":"International Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined species-specific mechanism (Cbl-b vs SHP-1), multiple functional readouts, single lab","pmids":["25239131"],"is_preprint":false},{"year":2013,"finding":"The CD72c allele is a hypofunctional allele for BCR signal inhibition and functions as a modifier gene that regulates Fas(lpr)-induced lupus-like autoimmune disease. Introduction of the chromosomal interval containing Cd72c caused lupus-like disease on B6/lpr background, while replacement of Cd72c with Cd72b in MRL/lpr congenic mice reduced disease severity.","method":"Congenic mouse generation, BCR signaling assays comparing CD72c vs CD72b, disease severity assessment (autoantibodies, CD4⁻CD8⁻ T cells)","journal":"Journal of Immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis using congenic strains plus BCR signaling functional comparison of alleles, multiple disease phenotype readouts","pmids":["23616572"],"is_preprint":false},{"year":2025,"finding":"Soluble CD72 (sCD72) binds to CD100 on the surface of T cells and enters the cytoplasm, suppressing T cell adaptive immune functions (reducing CD4+IFN-γ+, CD8+Perforin+, CD8+GZMB+, CD8+FASL+ populations and increasing CD4+TNF-α+ population) in a sepsis model.","method":"Recombinant sCD72 injection in CLP sepsis mouse model, flow cytometry of T cell subsets, confocal microscopy showing sCD72 entering T cell cytoplasm, CRISPR/Cas9 CD72-KO mice","journal":"International Immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO plus recombinant protein injection with defined cellular phenotypes, single lab, novel mechanism","pmids":["39793226"],"is_preprint":false},{"year":2024,"finding":"Soluble CD72 (sCD72) interacts with CD6 on activated CD4+ T cells (identified by mass spectrometry and co-immunoprecipitation) and increases pro-inflammatory cytokines (IL-17A, IFN-γ) and T cell proliferation, activating the SLP-76-AKT-mTOR pathway.","method":"Mass spectrometry, co-immunoprecipitation, flow cytometry for cytokine secretion, phosphorylation assay (SLP-76, AKT, mTOR), CFSE proliferation assay","journal":"Frontiers in Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mass spectrometry plus co-IP for receptor identification, multiple functional assays, single lab","pmids":["39026665"],"is_preprint":false}],"current_model":"CD72 is a type II transmembrane C-type lectin expressed on B cells (and also NK cells and mast cells) that functions primarily as an inhibitory co-receptor: its cytoplasmic ITIM1 recruits SHP-1 upon BCR-induced tyrosine phosphorylation to suppress BCR-mediated ERK activation, Ca²⁺ mobilization, and downstream signaling (NF-AT, NF-κB, MAPK, PI3K/Akt), while ITIM2 recruits Grb2 (and indirectly BLNK) to attenuate this negative signal; its natural ligand CD100/Sema4D induces tyrosine dephosphorylation of CD72 and SHP-1 dissociation, thereby relieving inhibition; CD72 also binds CD5 on T cells (mediating T-B communication), recognizes the lupus self-antigen Sm/RNP through its extracellular C-type lectin-like domain to specifically suppress TLR7-driven autoimmune B cell responses, and can recruit CD19 and activate PI3K to deliver positive signals; the CD72c hypofunctional allele, with altered charge in the membrane-distal extracellular domain, reduces Sm/RNP binding and is a modifier of lupus susceptibility."},"narrative":{"mechanistic_narrative":"CD72 is a type II transmembrane C-type lectin-like receptor that serves as a tunable inhibitory co-receptor governing B cell development and activation [PMID:2645579, PMID:10549631]. Its founding topology places the C-type lectin-like domain extracellularly with an inverted membrane orientation lacking an N-terminal signal peptide, defining it within a receptor superfamily including the asialoglycoprotein receptor and CD23 [PMID:2645579]. The cytoplasmic tail carries two ITIMs: tyrosine-phosphorylated ITIM1 recruits the phosphatase SHP-1 to deliver a strong negative signal, while ITIM2 recruits Grb2 (and an associated BLNK-containing complex) that moderates the SHP-1 signal [PMID:9590210, PMID:9740800, PMID:10820378, PMID:15816000]. BCR cross-linking drives CD72 tyrosine phosphorylation and SHP-1 association, and CD72 is itself an in vivo SHP-1 substrate whose phosphorylation correlates with BCR-induced growth arrest and apoptosis [PMID:9590210, PMID:9740800]. Through this ITIM/SHP-1 axis CD72 dampens BCR-induced ERK and Ca²⁺ mobilization, with downstream suppression of NF-AT, NF-κB, MAPK and PI3K/Akt signaling; an intact ITIM is required for inhibition [PMID:10640734, PMID:16621999]. Genetic loss of CD72 in mice perturbs B cell development and produces hyperproliferative, Ca²⁺-hyperresponsive B cells, and in antigen-specific anergic settings CD72-deficient B cells inappropriately survive and aged mice develop lupus-like autoimmunity, the latter linked to physical association with and regulation of Cbl-b [PMID:10549631, PMID:18821699]. The receptor's extracellular CTLD recognizes the RNA-containing lupus self-antigen Sm/RNP to specifically restrain TLR7-driven B cell responses; the hypofunctional CD72c allele shows altered charge at the ligand-binding site, weaker Sm/RNP binding, and acts as a modifier of lupus susceptibility [PMID:27810925, PMID:23616572]. CD72 binding partners include CD5 on T cells and the semaphorin CD100/Sema4D, whose engagement induces CD72 dephosphorylation and SHP-1 dissociation to switch off inhibitory signaling and set BCR signal sensitivity [PMID:1711157, PMID:1371783, PMID:11114375, PMID:12882840, PMID:16113236]. Beyond its inhibitory role, CD72 ligation can deliver positive, Syk-independent signals by activating Lyn, Blk and Btk and recruiting CD19-associated PI3-kinase [PMID:9531290, PMID:9808169]. CD72 functions analogously as an inhibitory receptor on NK cells and mast cells [PMID:20100931, PMID:19197938].","teleology":[{"year":1987,"claim":"Established that engaging CD72 (Lyb-2) triggers an intrinsic signaling response, distinct from cytokine pathways, indicating it is not merely a passive surface marker.","evidence":"Anti-Lyb-2 antibody-induced phosphatidylinositol hydrolysis assay in murine B cells with BSF-1 competition controls","pmids":["3499987"],"confidence":"Medium","gaps":["No molecular identity of the signaling intermediates","Allele specificity unexplained at the structural level"]},{"year":1989,"claim":"Defined the molecular architecture of CD72, resolving that it is an inverted type II C-type lectin-like receptor rather than a conventional receptor.","evidence":"cDNA sequencing and predicted topology analysis placing it in a C-type lectin superfamily with the asialoglycoprotein receptor and CD23","pmids":["2645579"],"confidence":"High","gaps":["No ligand identified at this stage","No functional consequence of the lectin fold tested"]},{"year":1991,"claim":"Identified the first CD72 binding partner, CD5 on T cells, establishing CD72 as a mediator of T-B cell communication.","evidence":"Biotin-labeled CD5 probe binding, antibody blocking, and gain-of-function CD72 transfection into non-B cells","pmids":["1711157","1371783"],"confidence":"High","gaps":["Downstream signaling consequence of CD5-CD72 binding not defined","Affinity and stoichiometry not quantified"]},{"year":1998,"claim":"Resolved the proximal signaling machinery, showing CD72's cytoplasmic ITIM recruits SHP-1 upon BCR-induced phosphorylation and that CD72 is an in vivo SHP-1 substrate whose phosphorylation tracks with growth arrest/apoptosis; also mapped both positive (Lyn/Blk/Btk, CD19-PI3K) and negative arms.","evidence":"ITIM phosphopeptide pull-down, co-IP from BCR-stimulated B cells, kinase activity assays, xid (Btk-deficient) B cells, and reciprocal CD19/CD72 co-IP","pmids":["9590210","9740800","9531290","9808169"],"confidence":"High","gaps":["How a single receptor switches between positive and negative outputs unresolved","CD19-CD72 association is transient and from a single lab (#7)"]},{"year":1998,"claim":"Identified the transcriptional basis of B-cell-restricted CD72 expression, linking lineage-specific gene control to PU.1.","evidence":"DNase I footprinting, EMSA, and reporter mutagenesis of the PU.1 site in B vs non-B cells","pmids":["9498769"],"confidence":"High","gaps":["Other regulatory inputs to CD72 expression not mapped","No link between expression level and signaling output"]},{"year":1999,"claim":"Demonstrated through genetics that CD72 is a nonredundant negative regulator of B cell activation and development in vivo, not merely an in vitro signaling artifact.","evidence":"CD72-knockout mice with B cell subset flow cytometry, proliferation, and intracellular Ca²⁺ measurements","pmids":["10549631"],"confidence":"High","gaps":["Did not connect phenotype to a physiological ligand","Developmental versus activation roles not mechanistically separated"]},{"year":2000,"claim":"Identified CD100/Sema4D as the physiological ligand and defined the regulatory logic: CD100 binding dephosphorylates CD72 and dissociates SHP-1, switching off inhibition; ITIM mutagenesis confirmed the ITIM is required for negative signaling; BLNK was placed in the CD72/SHP-1/Grb2 complex.","evidence":"Expression cloning, affinity measurement, dephosphorylation and SHP-1 dissociation assays, ITIM-mutant transfection with ERK/Ca²⁺ readouts, and quaternary complex co-IP","pmids":["11114375","10640734","10820378"],"confidence":"High","gaps":["BLNK complex shown by single-lab co-IP (#8)","How CD100 engagement mechanistically drives CD72 dephosphorylation not resolved"]},{"year":2005,"claim":"Dissected the two ITIMs functionally and established CD100 sets BCR signal sensitivity in vivo, with CD100 loss causing constitutive SHP-1 association, hyporesponsiveness, and aging autoimmunity.","evidence":"ITIM Tyr-to-Phe mutant panels with growth-inhibition readout and CD100-knockout mice with CD72-BCR co-IP and autoantibody measurement","pmids":["15816000","16113236"],"confidence":"High","gaps":["ITIM2/Grb2 moderation mechanism (#10) from single lab","Structural basis of constitutive CD72-BCR association unknown"]},{"year":2008,"claim":"Connected CD72 directly to tolerance and autoimmunity, showing it enforces anergy by limiting antigen-induced signaling and by regulating Cbl-b, with its loss producing lupus-like disease.","evidence":"CD72-knockout HEL-BCR transgenic mice, Ca²⁺/NF-κB/NFAT/MAPK/Akt assays, and Cbl-b co-IP","pmids":["18821699"],"confidence":"High","gaps":["Mechanism by which CD72 regulates Cbl-b not detailed","Did not identify the self-antigen recognized"]},{"year":2013,"claim":"Established the CD72c allele as a hypofunctional lupus modifier gene through genetic epistasis, linking allelic variation in CD72 to autoimmune disease severity.","evidence":"Congenic mouse strains with allele swaps and BCR signaling comparison plus disease scoring","pmids":["23616572"],"confidence":"High","gaps":["Structural/biochemical basis of CD72c hypofunction not yet defined at this step","Human relevance of the murine allele not addressed"]},{"year":2016,"claim":"Provided the structural and mechanistic explanation for CD72's autoimmune specificity, showing the extracellular CTLD directly binds Sm/RNP to suppress TLR7-driven responses and that CD72c bears charge alterations weakening this binding.","evidence":"CTLD-Sm/RNP binding assay, TLR7-dependent B cell inhibition assay, and X-ray crystallography of the CD72c CTLD","pmids":["27810925"],"confidence":"High","gaps":["Co-crystal structure of CTLD with Sm/RNP not solved","How CTLD ligand recognition couples to cytoplasmic ITIM signaling unresolved"]},{"year":2014,"claim":"Extended CD72 inhibitory function beyond B cells to NK cells and mast cells, revealing both shared (SHP-1) and species-divergent (Cbl-b) effector usage.","evidence":"Ectopic CD72 expression with IFN-γ readout in NK line, and CD72 ligation in human and mouse mast cells with SHP-1/Cbl-b co-IP and functional assays","pmids":["19197938","20100931","25239131"],"confidence":"Medium","gaps":["Mechanistic basis of human/mouse mast cell divergence unexplained","NK and mast cell findings each from single labs"]},{"year":2025,"claim":"Identified new ligands and a soluble form of CD72 acting on T cells, indicating CD72 functions beyond a membrane-bound B cell receptor.","evidence":"Sema3A co-IP and signaling in SLE B cells; soluble CD72 binding CD100 and CD6 on T cells with phenotypic and pathway readouts in sepsis and inflammation models","pmids":["36470209","39793226","39026665"],"confidence":"Medium","gaps":["Soluble CD72 mechanism (cytoplasmic entry, CD6/CD100 engagement) from single labs","Physiological source and abundance of soluble CD72 not established"]},{"year":null,"claim":"How extracellular CTLD ligand recognition (Sm/RNP, CD100, CD5, Sema3A) is structurally transmitted to the dual-ITIM cytoplasmic module to bias positive versus negative signaling remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of CD72 ectodomain bound to any ligand","No reconstituted model coupling ligand binding to ITIM phosphorylation state","Determinants selecting SHP-1 inhibition versus Lyn/Btk/CD19-PI3K activation undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,5,10,18]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[1,0,13]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[2,8,12]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[1,0]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[14,24]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[24]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,5,18,12]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,5,1,7]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[12,13,27]}],"complexes":[],"partners":["SHP-1","GRB2","CD100","CD5","CD19","BLNK","CBL-B","BTK"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P21854","full_name":"B-cell differentiation antigen CD72","aliases":["Lyb-2"],"length_aa":359,"mass_kda":40.2,"function":"Co-receptor of B cell receptor (BCR) that plays both positive and negative roles on B-cell functions. Recognizes the Sm/ribonucleoprotein (RNP) self-antigen ligand, and coligation of CD72 and BCR inhibits BCR signaling. Mechanistically, ligand binding leads to the recruitment of PTPN6/SHP-1 to the BCR complex which is inhibitory to BCR signaling. Also acts as a ligand for CD5 and thereby plays a critical role in maintaining regulatory T and B-cell homeostasis","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/P21854/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CD72","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CD72","total_profiled":1310},"omim":[{"mim_id":"604590","title":"Fc FRAGMENT OF IgG RECEPTOR IIb; FCGR2B","url":"https://www.omim.org/entry/604590"},{"mim_id":"601866","title":"SEMAPHORIN 4D; SEMA4D","url":"https://www.omim.org/entry/601866"},{"mim_id":"147683","title":"INTERLEUKIN 13; IL13","url":"https://www.omim.org/entry/147683"},{"mim_id":"107272","title":"CD72 ANTIGEN; CD72","url":"https://www.omim.org/entry/107272"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Nucleoplasm","reliability":"Uncertain"},{"location":"Mitochondria","reliability":"Uncertain"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":60.4}],"url":"https://www.proteinatlas.org/search/CD72"},"hgnc":{"alias_symbol":["LYB2","CD72b"],"prev_symbol":[]},"alphafold":{"accession":"P21854","domains":[{"cath_id":"3.10.100.10","chopping":"239-304_315-355","consensus_level":"high","plddt":81.0354,"start":239,"end":355},{"cath_id":"1.10.287","chopping":"175-228","consensus_level":"medium","plddt":94.6039,"start":175,"end":228}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P21854","model_url":"https://alphafold.ebi.ac.uk/files/AF-P21854-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P21854-F1-predicted_aligned_error_v6.png","plddt_mean":76.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CD72","jax_strain_url":"https://www.jax.org/strain/search?query=CD72"},"sequence":{"accession":"P21854","fasta_url":"https://rest.uniprot.org/uniprotkb/P21854.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P21854/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P21854"}},"corpus_meta":[{"pmid":"1711157","id":"PMC_1711157","title":"The B-cell surface protein CD72/Lyb-2 is the ligand for CD5.","date":"1991","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/1711157","citation_count":307,"is_preprint":false},{"pmid":"11114375","id":"PMC_11114375","title":"Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling.","date":"2000","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11114375","citation_count":296,"is_preprint":false},{"pmid":"10549631","id":"PMC_10549631","title":"CD72-deficient mice reveal nonredundant roles of CD72 in B cell development and activation.","date":"1999","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/10549631","citation_count":160,"is_preprint":false},{"pmid":"9590210","id":"PMC_9590210","title":"The B cell surface protein CD72 recruits the tyrosine phosphatase SHP-1 upon tyrosine phosphorylation.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9590210","citation_count":121,"is_preprint":false},{"pmid":"9740800","id":"PMC_9740800","title":"The B-cell transmembrane protein CD72 binds to and is an in vivo substrate of the protein tyrosine phosphatase SHP-1.","date":"1998","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/9740800","citation_count":97,"is_preprint":false},{"pmid":"11738997","id":"PMC_11738997","title":"The CD100-CD72 interaction: a novel mechanism of immune regulation.","date":"2001","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11738997","citation_count":95,"is_preprint":false},{"pmid":"12882840","id":"PMC_12882840","title":"Involvement of CD100, a lymphocyte semaphorin, in the activation of the human immune system via CD72: implications for the regulation of immune and inflammatory responses.","date":"2003","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12882840","citation_count":83,"is_preprint":false},{"pmid":"2645579","id":"PMC_2645579","title":"Sequence of the Lyb-2 B-cell differentiation antigen defines a gene superfamily of receptors with inverted membrane orientation.","date":"1989","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2645579","citation_count":81,"is_preprint":false},{"pmid":"6220106","id":"PMC_6220106","title":"On the function of Ly-5 in the regulation of antigen-driven B cell differentiation. Comparison and contrast with Lyb-2.","date":"1983","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/6220106","citation_count":79,"is_preprint":false},{"pmid":"7945782","id":"PMC_7945782","title":"B-cell signalling via the C-type lectins CD23 and CD72.","date":"1994","source":"Immunology today","url":"https://pubmed.ncbi.nlm.nih.gov/7945782","citation_count":75,"is_preprint":false},{"pmid":"10640734","id":"PMC_10640734","title":"CD72 negatively regulates signaling through the antigen receptor of B cells.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10640734","citation_count":75,"is_preprint":false},{"pmid":"1371783","id":"PMC_1371783","title":"Ly-1 (CD5), a membrane glycoprotein of mouse T lymphocytes and a subset of B cells, is a natural ligand of the B cell surface protein Lyb-2 (CD72).","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1371783","citation_count":67,"is_preprint":false},{"pmid":"15364057","id":"PMC_15364057","title":"Molecular interactions regulate BCR signal inhibition by CD22 and CD72.","date":"2004","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15364057","citation_count":66,"is_preprint":false},{"pmid":"11043769","id":"PMC_11043769","title":"CD72, a negative regulator of B-cell responsiveness.","date":"2000","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/11043769","citation_count":60,"is_preprint":false},{"pmid":"6969779","id":"PMC_6969779","title":"Lyb-2 system of mouse B cells. Evidence for a role in the generation of antibody-forming cells.","date":"1981","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/6969779","citation_count":60,"is_preprint":false},{"pmid":"33727310","id":"PMC_33727310","title":"Surface Proteomics Reveals CD72 as a Target for In Vitro-Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL.","date":"2021","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/33727310","citation_count":59,"is_preprint":false},{"pmid":"34100920","id":"PMC_34100920","title":"Single-cell transcriptomic analyses of cardiac immune cells reveal that Rel-driven CD72-positive macrophages induce cardiomyocyte injury.","date":"2022","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/34100920","citation_count":53,"is_preprint":false},{"pmid":"2141045","id":"PMC_2141045","title":"Identification of a human protein homologous to the mouse Lyb-2 B cell differentiation antigen and sequence of the corresponding cDNA.","date":"1990","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/2141045","citation_count":53,"is_preprint":false},{"pmid":"8671676","id":"PMC_8671676","title":"Antigen receptor-mediated B cell death is blocked by signaling via CD72 or treatment with dextran sulfate and is defective in autoimmunity-prone mice.","date":"1996","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8671676","citation_count":50,"is_preprint":false},{"pmid":"8757302","id":"PMC_8757302","title":"The CD5/CD72 receptor system is coexpressed with several functionally relevant counterstructures on human B cells and delivers a critical signaling activity.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8757302","citation_count":46,"is_preprint":false},{"pmid":"3281760","id":"PMC_3281760","title":"Properties of anti-Lyb-2-mediated B-cell activation and the relationship between Lyb-2 molecules and receptors for B-cell stimulatory factor-1 on murine B lymphocytes.","date":"1988","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/3281760","citation_count":42,"is_preprint":false},{"pmid":"9808169","id":"PMC_9808169","title":"CD72-mediated B cell activation involves recruitment of CD19 and activation of phosphatidylinositol 3-kinase.","date":"1998","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9808169","citation_count":41,"is_preprint":false},{"pmid":"16113236","id":"PMC_16113236","title":"Requirement for CD100-CD72 interactions in fine-tuning of B-cell antigen receptor signaling and homeostatic maintenance of the B-cell compartment.","date":"2005","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16113236","citation_count":41,"is_preprint":false},{"pmid":"18821699","id":"PMC_18821699","title":"Modulation of peripheral B cell tolerance by CD72 in a murine model.","date":"2008","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/18821699","citation_count":40,"is_preprint":false},{"pmid":"27810925","id":"PMC_27810925","title":"CD72 negatively regulates B lymphocyte responses to the lupus-related endogenous toll-like receptor 7 ligand Sm/RNP.","date":"2016","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27810925","citation_count":39,"is_preprint":false},{"pmid":"19067131","id":"PMC_19067131","title":"CD72, a coreceptor with both positive and negative effects on B lymphocyte development and function.","date":"2008","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19067131","citation_count":38,"is_preprint":false},{"pmid":"1828426","id":"PMC_1828426","title":"Stimulation of B lymphocytes via CD72 (human Lyb-2).","date":"1991","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1828426","citation_count":38,"is_preprint":false},{"pmid":"3091682","id":"PMC_3091682","title":"A role for Lyb-2 in B cell activation mediated by a B cell stimulatory factor.","date":"1986","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3091682","citation_count":37,"is_preprint":false},{"pmid":"24950378","id":"PMC_24950378","title":"Interaction of CD5 and CD72 is involved in regulatory T and B cell homeostasis.","date":"2014","source":"Immunological investigations","url":"https://pubmed.ncbi.nlm.nih.gov/24950378","citation_count":36,"is_preprint":false},{"pmid":"9531290","id":"PMC_9531290","title":"Activation of lyn, blk, and btk but not syk in CD72-stimulated B lymphocytes.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9531290","citation_count":36,"is_preprint":false},{"pmid":"24461079","id":"PMC_24461079","title":"A regulatory role for CD72 expression on B cells in systemic lupus erythematosus.","date":"2013","source":"Seminars in arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/24461079","citation_count":33,"is_preprint":false},{"pmid":"20100931","id":"PMC_20100931","title":"CD72 negatively regulates KIT-mediated responses in human mast cells.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20100931","citation_count":33,"is_preprint":false},{"pmid":"15459183","id":"PMC_15459183","title":"CD72 polymorphisms associated with alternative splicing modify susceptibility to human systemic lupus erythematosus through epistatic interaction with FCGR2B.","date":"2004","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15459183","citation_count":33,"is_preprint":false},{"pmid":"1634777","id":"PMC_1634777","title":"Extensive polymorphism in the extracellular domain of the mouse B cell differentiation antigen Lyb-2/CD72.","date":"1992","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1634777","citation_count":33,"is_preprint":false},{"pmid":"10820378","id":"PMC_10820378","title":"BLNK is associated with the CD72/SHP-1/Grb2 complex in the WEHI231 cell line after membrane IgM cross-linking.","date":"2000","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10820378","citation_count":31,"is_preprint":false},{"pmid":"16621999","id":"PMC_16621999","title":"CD72 down-modulates BCR-induced signal transduction and diminishes survival in primary mature B lymphocytes.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16621999","citation_count":30,"is_preprint":false},{"pmid":"11466342","id":"PMC_11466342","title":"Positive signaling through CD72 induces mitogen-activated protein kinase activation and synergizes with B cell receptor signals to induce X-linked immunodeficiency B cell proliferation.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11466342","citation_count":30,"is_preprint":false},{"pmid":"17786190","id":"PMC_17786190","title":"CD100 on NK cells enhance IFNgamma secretion and killing of target cells expressing CD72.","date":"2007","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/17786190","citation_count":29,"is_preprint":false},{"pmid":"7287083","id":"PMC_7287083","title":"Ly-m19: the Lyb-2 region of mouse chromosome 4 controls a new surface alloantigen.","date":"1981","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/7287083","citation_count":29,"is_preprint":false},{"pmid":"7876545","id":"PMC_7876545","title":"Structure of the mouse CD72 (Lyb-2) gene and its alternatively spliced transcripts.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7876545","citation_count":25,"is_preprint":false},{"pmid":"23616572","id":"PMC_23616572","title":"Cd72(c) is a modifier gene that regulates Fas(lpr)-induced autoimmune disease.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23616572","citation_count":25,"is_preprint":false},{"pmid":"2044654","id":"PMC_2044654","title":"Identity of human Lyb-2 and CD72 and localization of the gene to chromosome 9.","date":"1991","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/2044654","citation_count":24,"is_preprint":false},{"pmid":"11999169","id":"PMC_11999169","title":"Positive and negative roles of CD72 in B cell function.","date":"2002","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/11999169","citation_count":23,"is_preprint":false},{"pmid":"17364492","id":"PMC_17364492","title":"Down-regulation of CD72 and increased surface IgG on B cells in patients with lupus nephritis.","date":"2007","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/17364492","citation_count":23,"is_preprint":false},{"pmid":"7683586","id":"PMC_7683586","title":"Expression of CD5 and CD72 on T and B cell subsets in rheumatoid arthritis and Sjögren's syndrome.","date":"1993","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7683586","citation_count":23,"is_preprint":false},{"pmid":"28713384","id":"PMC_28713384","title":"Intact CD100-CD72 Interaction Necessary for TCR-Induced T Cell Proliferation.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28713384","citation_count":23,"is_preprint":false},{"pmid":"30161254","id":"PMC_30161254","title":"CD72/CD100 and PD-1/PD-L1 markers are increased on T and B cells in HIV-1+ viremic individuals, and CD72/CD100 axis is correlated with T-cell exhaustion.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30161254","citation_count":23,"is_preprint":false},{"pmid":"3499987","id":"PMC_3499987","title":"Early events in B-cell activation: anti-Lyb2, but not BSF-1, induces a phosphatidylinositol response in murine B cells.","date":"1987","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/3499987","citation_count":22,"is_preprint":false},{"pmid":"6175719","id":"PMC_6175719","title":"Evidence that Lyb-2 is critical to specific activation of B cells before they become responsive to T cell and other signals.","date":"1982","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/6175719","citation_count":22,"is_preprint":false},{"pmid":"1717562","id":"PMC_1717562","title":"Differential regulation of surface Ig- and Lyb2-mediated B cell activation by cyclic AMP. I. Evidence for alternative regulation of signaling through two different receptors linked to phosphatidylinositol hydrolysis in murine B cells.","date":"1991","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/1717562","citation_count":21,"is_preprint":false},{"pmid":"1384316","id":"PMC_1384316","title":"Human Lyb-2 homolog CD72 is a marker for progenitor B-cell leukemias.","date":"1992","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/1384316","citation_count":21,"is_preprint":false},{"pmid":"3260915","id":"PMC_3260915","title":"Differential regulation by Ly-5 and Lyb-2 of IgG production induced by lipopolysaccharide and B cell stimulatory factor-1 (IL-4).","date":"1988","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3260915","citation_count":21,"is_preprint":false},{"pmid":"38007238","id":"PMC_38007238","title":"Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies.","date":"2023","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38007238","citation_count":20,"is_preprint":false},{"pmid":"9498769","id":"PMC_9498769","title":"PU.1/Spi-1 is essential for the B cell-specific activity of the mouse CD72 promoter.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9498769","citation_count":20,"is_preprint":false},{"pmid":"14989715","id":"PMC_14989715","title":"Increased expression of the B-cell-regulatory molecule CD72 in primary Sjögren's syndrome.","date":"2004","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/14989715","citation_count":18,"is_preprint":false},{"pmid":"30838156","id":"PMC_30838156","title":"CD72 is a Negative Regulator of B Cell Responses to Nuclear Lupus Self-antigens and Development of Systemic Lupus Erythematosus.","date":"2019","source":"Immune network","url":"https://pubmed.ncbi.nlm.nih.gov/30838156","citation_count":17,"is_preprint":false},{"pmid":"1388135","id":"PMC_1388135","title":"Occupancy of CD72 (the CD5 counterstructure) enhances interleukin-4-dependent CD23 expression in resting B lymphocytes.","date":"1992","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1388135","citation_count":17,"is_preprint":false},{"pmid":"16047337","id":"PMC_16047337","title":"CD72-mediated suppression of human naive B cell differentiation by down-regulating X-box binding protein 1.","date":"2005","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16047337","citation_count":16,"is_preprint":false},{"pmid":"15816000","id":"PMC_15816000","title":"Dual regulation of BCR-mediated growth inhibition signaling by CD72.","date":"2005","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15816000","citation_count":16,"is_preprint":false},{"pmid":"19197938","id":"PMC_19197938","title":"B-cell co-receptor CD72 is expressed on NK cells and inhibits IFN-gamma production but not cytotoxicity.","date":"2009","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19197938","citation_count":15,"is_preprint":false},{"pmid":"26883681","id":"PMC_26883681","title":"Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis.","date":"2016","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/26883681","citation_count":15,"is_preprint":false},{"pmid":"1535509","id":"PMC_1535509","title":"Regulation of lipopolysaccharide- and IL-4-induced immunoglobulin heavy chain gene activation: differential roles for CD45 and Lyb-2.","date":"1992","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1535509","citation_count":15,"is_preprint":false},{"pmid":"8995186","id":"PMC_8995186","title":"Allele-specific expression of the mouse B-cell surface protein CD72 on T cells.","date":"1997","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/8995186","citation_count":14,"is_preprint":false},{"pmid":"28419421","id":"PMC_28419421","title":"Upregulation of CD72 expression on CD19+ CD27+ memory B cells by CD40L in primary immune thrombocytopenia.","date":"2017","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/28419421","citation_count":14,"is_preprint":false},{"pmid":"18071878","id":"PMC_18071878","title":"CD72 polymorphism associated with child-onset of idiopathic thrombocytopenic purpura in Chinese patients.","date":"2008","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18071878","citation_count":14,"is_preprint":false},{"pmid":"22606231","id":"PMC_22606231","title":"Placental expression of CD100, CD72 and CD45 is dysregulated in human miscarriage.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22606231","citation_count":13,"is_preprint":false},{"pmid":"8409435","id":"PMC_8409435","title":"Biochemical identity of the mouse Ly-19.2 and Ly-32.2 alloantigens with the B cell differentiation antigen Lyb-2/CD72.","date":"1993","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8409435","citation_count":13,"is_preprint":false},{"pmid":"14563017","id":"PMC_14563017","title":"Structure and function of CD72 in the non-obese diabetic (NOD) mouse.","date":"2003","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/14563017","citation_count":11,"is_preprint":false},{"pmid":"17121583","id":"PMC_17121583","title":"Increased mutations of CD72 transcript in B-lymphocytes from adolescent patients with systemic lupus erythematosus.","date":"2006","source":"Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17121583","citation_count":11,"is_preprint":false},{"pmid":"23268649","id":"PMC_23268649","title":"Human CD72 splicing isoform responsible for resistance to systemic lupus erythematosus regulates serum immunoglobulin level and is localized in endoplasmic reticulum.","date":"2012","source":"BMC immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23268649","citation_count":11,"is_preprint":false},{"pmid":"15148289","id":"PMC_15148289","title":"Impairment of B cell receptor-mediated Ca2+ influx, activation of mitogen-activated protein kinases and growth inhibition in CD72-deficient BAL-17 cells.","date":"2004","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15148289","citation_count":11,"is_preprint":false},{"pmid":"31883832","id":"PMC_31883832","title":"CD22 and CD72 contribute to the development of scleroderma in a murine model.","date":"2019","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/31883832","citation_count":10,"is_preprint":false},{"pmid":"32306893","id":"PMC_32306893","title":"A regulatory role for CD72 expression on B cells and increased soluble CD72 in primary Sjogren's syndrome.","date":"2020","source":"BMC immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32306893","citation_count":10,"is_preprint":false},{"pmid":"9237109","id":"PMC_9237109","title":"Modulation of CD72 by ligation of B cell receptor complex molecules on CD5+ B cells.","date":"1997","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9237109","citation_count":10,"is_preprint":false},{"pmid":"8580813","id":"PMC_8580813","title":"An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia.","date":"1995","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/8580813","citation_count":10,"is_preprint":false},{"pmid":"3169880","id":"PMC_3169880","title":"Biochemical similarity of Ly-19, Ly-32, and Lyb-2 alloantigens encoded in the gene cluster on mouse chromosome 4.","date":"1988","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/3169880","citation_count":10,"is_preprint":false},{"pmid":"8398988","id":"PMC_8398988","title":"Differential regulation of surface immunoglobulin and Lyb2 mediated B cell activation: II. cAMP dependent (prostaglandin E2) and independent (IFN-gamma) mechanisms of regulation of B lymphocyte activation.","date":"1993","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8398988","citation_count":9,"is_preprint":false},{"pmid":"23184497","id":"PMC_23184497","title":"Modulation of B cell regulatory molecules CD22 and CD72 in myasthenia gravis and multiple sclerosis.","date":"2013","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/23184497","citation_count":9,"is_preprint":false},{"pmid":"36470209","id":"PMC_36470209","title":"CD72-semaphorin3A axis: A new regulatory pathway in systemic lupus erythematosus.","date":"2022","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/36470209","citation_count":8,"is_preprint":false},{"pmid":"24713856","id":"PMC_24713856","title":"CD72 regulates the growth of KIT-mutated leukemia cell line Kasumi-1.","date":"2013","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/24713856","citation_count":8,"is_preprint":false},{"pmid":"29922261","id":"PMC_29922261","title":"CD100/Sema4D Increases Macrophage Infection by Leishmania (Leishmania) amazonensis in a CD72 Dependent Manner.","date":"2018","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/29922261","citation_count":8,"is_preprint":false},{"pmid":"28222623","id":"PMC_28222623","title":"Interferon-α-induced CD100 on naïve CD8+ T cells enhances antiviral responses to hepatitis C infection through CD72 signal transduction.","date":"2017","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/28222623","citation_count":8,"is_preprint":false},{"pmid":"25239131","id":"PMC_25239131","title":"CD72 negatively regulates mouse mast cell functions and down-regulates the expression of KIT and FcεRIα.","date":"2014","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25239131","citation_count":7,"is_preprint":false},{"pmid":"16581823","id":"PMC_16581823","title":"A novel avian homologue of CD72, chB1r, down modulates BCR-mediated activation signals.","date":"2006","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16581823","citation_count":7,"is_preprint":false},{"pmid":"14734859","id":"PMC_14734859","title":"CD72 stimulation modulates anti-IgM induced apoptotic signaling through the pathway of NF-kappaB, c-Myc and p27(Kip1).","date":"2004","source":"Microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14734859","citation_count":7,"is_preprint":false},{"pmid":"9023424","id":"PMC_9023424","title":"CD72 ligation regulates defective naive newborn B cell responses.","date":"1997","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9023424","citation_count":7,"is_preprint":false},{"pmid":"2957071","id":"PMC_2957071","title":"B-cell activation stimulated by monoclonal anti-Lyb2.1 antibody is mediated through a receptor distinct from the BSF-1 receptor.","date":"1987","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/2957071","citation_count":6,"is_preprint":false},{"pmid":"23365086","id":"PMC_23365086","title":"A bacterial artificial chromosome transgene with polymorphic Cd72 inhibits the development of glomerulonephritis and vasculitis in MRL-Faslpr lupus mice.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23365086","citation_count":6,"is_preprint":false},{"pmid":"38664244","id":"PMC_38664244","title":"Asiaticoside alleviates lipopolysaccharide-induced acute lung injury by blocking Sema4D/CD72 and inhibiting mitochondrial dysfunction in RAW264.7 cell and mice.","date":"2024","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38664244","citation_count":5,"is_preprint":false},{"pmid":"7681409","id":"PMC_7681409","title":"Stimulation of tyrosine phosphorylation without inositol lipid hydrolysis in human B lymphocytes on engaging CD72.","date":"1993","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/7681409","citation_count":5,"is_preprint":false},{"pmid":"39026665","id":"PMC_39026665","title":"Soluble CD72, is a T-cell activator probably via binding to CD6 in homeostasis and autoimmunity.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39026665","citation_count":4,"is_preprint":false},{"pmid":"39326825","id":"PMC_39326825","title":"Integrative transcriptomic analysis reveals Cd72 as a novel pro-inflammatory factor in microglia following experimental ischemic stroke.","date":"2024","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/39326825","citation_count":3,"is_preprint":false},{"pmid":"11491534","id":"PMC_11491534","title":"R-phycoerythrin-cyanine 5 tandem discerns CD72 polymorphism.","date":"2001","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11491534","citation_count":3,"is_preprint":false},{"pmid":"39793226","id":"PMC_39793226","title":"Soluble CD72 concurrently impairs T cell functions while enhances inflammatory response in sepsis.","date":"2025","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39793226","citation_count":3,"is_preprint":false},{"pmid":"31262443","id":"PMC_31262443","title":"CD22 and CD72 cooperatively contribute to the development of the reverse Arthus reaction model.","date":"2019","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/31262443","citation_count":3,"is_preprint":false},{"pmid":"19167349","id":"PMC_19167349","title":"Centromeric interval of chromosome 4 derived from C57BL/6 mice accelerates type 1 diabetes in NOD.CD72b congenic mice.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19167349","citation_count":3,"is_preprint":false},{"pmid":"17023047","id":"PMC_17023047","title":"Various domains of the B-cell regulatory molecule CD72 has diverged at different rates in mammals: cloning, transcription and mapping of porcine CD72.","date":"2006","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17023047","citation_count":3,"is_preprint":false},{"pmid":"37876342","id":"PMC_37876342","title":"CD72 is a pan-tumor antigen associated to pediatric acute leukemia.","date":"2023","source":"Cytometry. Part A : the journal of the International Society for Analytical Cytology","url":"https://pubmed.ncbi.nlm.nih.gov/37876342","citation_count":2,"is_preprint":false},{"pmid":"36326455","id":"PMC_36326455","title":"Blockage of CD72 reduces B cell proliferation in immune thrombocytopenic purpura, involving interleukin 1 and macrophage migration inhibitory factor secretion.","date":"2022","source":"Hematology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/36326455","citation_count":2,"is_preprint":false},{"pmid":"9576009","id":"PMC_9576009","title":"Selective response of CD5+ B cell malignancies to activation of the CD72 antigen.","date":"1998","source":"Clinical immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/9576009","citation_count":2,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48418,"output_tokens":7920,"usd":0.132027,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17359,"output_tokens":4820,"usd":0.103648,"stage2_stop_reason":"end_turn"},"total_usd":0.235675,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1991,\n      \"finding\": \"CD72 (Lyb-2) on B cells is the ligand for CD5 on T cells. Purified biotinylated CD5 protein specifically bound CD72-expressing cells; binding was blocked by anti-CD72 antibodies; non-B cells (mouse L-cell fibroblasts and human Jurkat T cells) transfected with human CD72 cDNA acquired the ability to bind CD5-biotin conjugate.\",\n      \"method\": \"Biotin-labeled CD5 probe binding assay, antibody blocking, transfection of CD72 cDNA into non-B cells\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct binding assay with purified protein, gain-of-function transfection, blocking antibody confirmation, independently replicated in mouse system (PMID:1371783)\",\n      \"pmids\": [\"1711157\", \"1371783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CD72 is the receptor for the class IV semaphorin CD100/Sema4D on lymphocytes (Kd ≈ 3×10⁻⁷ M). CD100 stimulation induces tyrosine dephosphorylation of CD72 and dissociation of SHP-1 from CD72, thereby switching off CD72-mediated negative signaling in B cells.\",\n      \"method\": \"Expression cloning, binding affinity measurements, tyrosine phosphorylation assay, co-immunoprecipitation of SHP-1 from CD72\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — expression cloning identification plus biochemical dephosphorylation and SHP-1 dissociation assays, replicated with human proteins (PMID:12882840) and in vivo (PMID:16113236)\",\n      \"pmids\": [\"11114375\", \"12882840\", \"16113236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The cytoplasmic domain of CD72 carries an ITIM that, upon tyrosine phosphorylation, recruits the tyrosine phosphatase SHP-1. BCR cross-linking enhances tyrosine phosphorylation of CD72 and its association with SHP-1 in B-cell line WEHI-231.\",\n      \"method\": \"In vitro ITIM phosphopeptide pull-down, co-immunoprecipitation from BCR-stimulated B cells\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro ITIM-SHP-1 interaction plus BCR-stimulated co-IP in cell line; independently confirmed by multiple labs (PMID:9740800, PMID:10549631)\",\n      \"pmids\": [\"9590210\", \"9740800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CD72 is an in vivo substrate of SHP-1 in B cells. Tyrosine phosphorylation of CD72 strongly correlates with BCR-induced growth arrest/apoptosis. The binding sites for SHP-1 and the adaptor Grb2 on CD72 were defined. Preligation of CD72 attenuated BCR-induced growth arrest/death signals in B cells.\",\n      \"method\": \"Co-immunoprecipitation from primary B cells and B-cell lines, correlation of CD72 phosphorylation with apoptosis, CD72 preligation rescue assay\",\n      \"journal\": \"Current Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo substrate identification with defined binding sites, multiple orthogonal methods (co-IP, functional rescue), confirmed in primary B cells\",\n      \"pmids\": [\"9740800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CD72-deficient mice show: (1) reduced mature recirculating B cells and accumulation of pre-B cells in bone marrow; (2) fewer mature B-2 cells and more B-1 cells in periphery; (3) hyperproliferative B cells and enhanced Ca²⁺ response following IgM cross-linking. CD72 is thus a nonredundant regulator of B cell development and a negative regulator of B cell activation.\",\n      \"method\": \"Gene knockout mouse model, flow cytometry of B cell subsets, proliferation assays, intracellular Ca²⁺ measurement\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with multiple defined cellular phenotypes (development and activation), orthogonal readouts (Ca²⁺, proliferation, subset counting)\",\n      \"pmids\": [\"10549631\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CD72 negatively regulates BCR signaling through its ITIM motif. Expression of CD72 in B lymphoma K46 cells down-modulates BCR-induced ERK activation and Ca²⁺ mobilization; this inhibition requires the intact ITIM, as an ITIM-mutated CD72 did not reduce ERK activation. Co-ligation of CD72 with BCR in normal spleen B cells also reduced BCR-mediated ERK activation.\",\n      \"method\": \"Transfection of wild-type vs. ITIM-mutant CD72, ERK activation assay, Ca²⁺ mobilization assay, co-ligation experiments in primary B cells\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — active-site (ITIM) mutagenesis combined with functional readouts (ERK, Ca²⁺) in cell lines and primary cells\",\n      \"pmids\": [\"10640734\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CD72 ligation activates Src-family kinases Lyn and Blk, and the Tec-family kinase Btk, but not Syk. Btk is required for CD72-induced B cell proliferation, as B cells from xid (Btk-deficient) mice are unresponsive to CD72-induced proliferation. CD72-mediated PLC-γ2 tyrosine phosphorylation occurs independently of Syk activation.\",\n      \"method\": \"Kinase activity assays after CD72 ligation, xid (Btk-deficient) mouse B cells, PLC-γ2 phosphorylation assay\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — defined kinase activation hierarchy with genetic (xid) validation, multiple orthogonal biochemical assays\",\n      \"pmids\": [\"9531290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CD72 ligation recruits CD19 and activates CD19-associated PI 3-kinase. CD72 ligation induces CD19 tyrosine phosphorylation and a transient physical association between CD19 and CD72. PI 3-K inhibitors block CD72-stimulated B cell proliferation. CD72 signaling is Syk-independent even when co-cross-linked with CD19.\",\n      \"method\": \"PI 3-K inhibitor assays, CD19 phosphorylation, co-immunoprecipitation of CD72 and CD19\",\n      \"journal\": \"European Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP and functional inhibition, single lab, two orthogonal approaches\",\n      \"pmids\": [\"9808169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The adaptor protein BLNK is associated with the CD72/SHP-1/Grb2 complex via the SH3 domain(s) of Grb2 in WEHI-231 cells after mIgM engagement, forming a CD72/SHP-1/Grb2/BLNK complex.\",\n      \"method\": \"Co-immunoprecipitation from BCR-stimulated WEHI-231 cells\",\n      \"journal\": \"European Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP demonstrating quaternary complex, single lab, confirmed in normal primary B cells\",\n      \"pmids\": [\"10820378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CD72 ligation induces ERK and JNK (but not p38) MAPK activation via PKC-dependent pathways, and CD72 signaling compensates for defective BCR signaling in Btk-deficient (xid) B cells, partially restoring proliferation to anti-IgM. This establishes CD72 as capable of inducing BCR-independent positive signaling.\",\n      \"method\": \"MAPK activation assays, PKC inhibitors, xid mouse B cells, proliferation assays\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic (xid) and pharmacological validation, single lab, multiple kinase pathway readouts\",\n      \"pmids\": [\"11466342\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CD72 ITIM1 (which binds SHP-1) delivers a strong negative signal that is attenuated by ITIM2 (which binds Grb2). ITIM1-only mutants (Y7/F) showed the least sensitivity to growth inhibition, double ITIM mutants (Y7,39/F) were also less sensitive, and Y39/F (ITIM2 mutant) cells were unrecoverable, suggesting ITIM2/Grb2 acts as a moderator of ITIM1/SHP-1 negative signaling.\",\n      \"method\": \"ITIM tyrosine-to-phenylalanine mutagenesis in retroviral vectors, BCR cross-linking growth inhibition assay\",\n      \"journal\": \"European Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — active-site mutagenesis (multiple ITIM point mutants) with defined functional readout, single lab\",\n      \"pmids\": [\"15816000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CD100 regulates BCR signal sensitivity by preventing constitutive association of CD72 with the BCR. In CD100-deficient mice, BCR signals are suppressed due to constitutive SHP-1 association with CD72, causing B-cell hyporesponsiveness and, with aging, accumulation of marginal zone B cells, elevated autoantibodies, and autoimmunity.\",\n      \"method\": \"CD100-knockout mice, BCR co-immunoprecipitation with CD72, B-cell functional assays, flow cytometry, autoantibody measurement\",\n      \"journal\": \"International Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO combined with biochemical co-IP demonstrating CD72-BCR association, multiple in vivo phenotypic readouts\",\n      \"pmids\": [\"16113236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In anergic B cells, CD72 down-regulates BCR signaling by limiting antigen-induced Ca²⁺ elevation and activation of NFATc1, NF-κB, MAPK, and Akt. CD72 is physically associated with and regulates the molecular adaptor Cbl-b in anergic B cells. CD72-deficient anergic B cells inappropriately proliferate and survive in response to self antigen, and aged CD72-deficient mice develop lupus-like autoimmune disease.\",\n      \"method\": \"CD72-knockout mice crossed with HEL-specific BCR transgenic mice, Ca²⁺ flux measurements, NF-κB/NFAT/MAPK/Akt signaling assays, co-immunoprecipitation of Cbl-b\",\n      \"journal\": \"Arthritis and Rheumatism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO in antigen-specific transgenic system, multiple signaling pathway readouts, co-IP of novel Cbl-b interaction\",\n      \"pmids\": [\"18821699\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CD72 binds the RNA-containing lupus self-antigen Sm/RNP through its extracellular C-type lectin-like domain (CTLD) and specifically inhibits B cell responses to Sm/RNP. X-ray crystallographic analysis of the lupus-susceptible CD72c allele CTLD reveals considerable alteration in charge at the putative ligand-binding site, which correlates with weaker Sm/RNP binding by CD72c compared with the lupus-resistant CD72a allele.\",\n      \"method\": \"CTLD-Sm/RNP binding assay, TLR7-dependent B cell response inhibition assay, x-ray crystallography of CD72c CTLD\",\n      \"journal\": \"Journal of Experimental Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with direct binding assay and functional B cell inhibition assay demonstrating allele-specific mechanism\",\n      \"pmids\": [\"27810925\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"CD72 (Lyb-2) is a type II transmembrane protein with inverted membrane orientation (C-terminus extracellular), lacking an N-terminal signal peptide, and is homologous to the asialoglycoprotein receptor and CD23, defining a gene superfamily of C-type lectin-like receptors with inverted orientation.\",\n      \"method\": \"cDNA sequencing, sequence comparison, predicted protein topology analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences USA\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct cDNA sequencing with structural prediction validated by expression, founding structural characterization replicated across species\",\n      \"pmids\": [\"2645579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CD72 is expressed on human mast cells. Ligation of CD72 (by agonistic antibody or recombinant CD100) induces CD72 tyrosine phosphorylation and increased association with SHP-1, resulting in inhibition of KIT-induced Src family kinase and ERK1/2 phosphorylation. This reduces KIT-mediated mast cell proliferation, chemotaxis, and chemokine production.\",\n      \"method\": \"Flow cytometry for CD72 expression, co-immunoprecipitation of SHP-1 with CD72, phosphorylation assays, proliferation and chemotaxis assays\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP showing SHP-1 recruitment, multiple functional readouts (proliferation, chemotaxis, cytokine), two activating stimuli tested\",\n      \"pmids\": [\"20100931\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CD72 is expressed on mouse NK cells and inhibits IFN-γ production but not cytotoxicity. Ectopic expression of CD72 in the NK-cell line KY2 inhibits cytokine-induced IFN-γ production; this inhibitory effect is diminished by mutations in the intracellular inhibitory motifs or replacement of the extracellular domain.\",\n      \"method\": \"Ectopic CD72 expression in NK cell line, IFN-γ production assay, intracellular domain mutants, cytotoxicity assay\",\n      \"journal\": \"European Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function expression plus domain mutants in NK cell line, single lab, two functional readouts\",\n      \"pmids\": [\"19197938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PU.1/Spi-1 binds the CD72 promoter (footprint FP I) and is essential for B cell-specific promoter activity. Mutation of the PU.1 binding site abolishes B cell-specific CD72 promoter activity in transient reporter assays.\",\n      \"method\": \"DNase I footprinting, EMSA, reporter gene deletion and mutation analysis in B cells vs. non-B cells\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — footprinting, EMSA, and mutagenesis of transcription factor binding site demonstrating necessity of PU.1 for promoter activity\",\n      \"pmids\": [\"9498769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CD72 loss-of-function in mature B lymphocytes (CD72-deficient HEL BCR transgenic mice) down-regulates BCR-induced NF-AT, NF-κB, ERK, JNK, p38-MAPK, and PI3K/Akt signaling pathways. CD72 ligation (mimicking CD100 binding) augments Ca²⁺ flux, IκBα activation, and ERK activity upon antigen stimulation, and CD72 promotes cell cycle arrest and apoptosis after antigen stimulation.\",\n      \"method\": \"CD72-knockout BCR-transgenic mice, luciferase reporter assays for NF-AT/NF-κB, MAPK/PI3K-Akt signaling assays, Ca²⁺ flux measurement, cell cycle and apoptosis analysis\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO in antigen-specific BCR transgenic system, comprehensive signaling pathway mapping with multiple orthogonal methods\",\n      \"pmids\": [\"16621999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CD72 loss-of-function in B cells (CD72-deficient BAL-17 cells) impairs BCR-mediated phosphorylation of CD19, Btk, Vav, and PLC-γ2, and CD19-PI3K association. Ca²⁺ release from intracellular stores is intact but extracellular Ca²⁺ influx is severely impaired. BCR-evoked ERK and JNK activation and growth inhibition are also blocked; these effects are reversed by re-expression of CD72.\",\n      \"method\": \"CD72-deficient B-cell lines generated from BAL-17 cells, phosphorylation assays, Ca²⁺ influx measurement, re-expression rescue experiment\",\n      \"journal\": \"International Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function cell line with rescue by re-expression, comprehensive signaling pathway analysis, multiple orthogonal readouts\",\n      \"pmids\": [\"15148289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CD72 cross-linking in human naive B cells suppresses differentiation into plasma cells by down-regulating X-box binding protein 1 (XBP-1) and CD27 expression, without affecting PRDI-BF1. This inhibition is dependent on the stimulation context (SAC+IL-2 but not CD40 signaling or CpG).\",\n      \"method\": \"CD72 cross-linking, XBP-1 and PRDI-BF1 expression analysis, Ig synthesis measurement, CD27 flow cytometry\",\n      \"journal\": \"European Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined molecular target (XBP-1) with context-dependent functional readouts, single lab\",\n      \"pmids\": [\"16047337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"Ligation of Lyb-2 (CD72) via monoclonal antibody induces phosphatidylinositol (PI) hydrolysis in murine B cells in a dose-dependent, allele-specific manner. This PI response is distinct from that induced by BSF-1 (IL-4), which does not induce a PI response and does not competitively inhibit anti-Lyb-2-induced PI turnover, indicating CD72 uses a different signaling pathway from BSF-1.\",\n      \"method\": \"PI metabolism assay in B cells, dose-response and allele-specificity controls, BSF-1 competition assay\",\n      \"journal\": \"Cellular Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct biochemical assay (PI hydrolysis) with allele-specificity and competition controls, single lab\",\n      \"pmids\": [\"3499987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CD72 stimulation of immature B cells (WEHIdelta) prevents BCR-induced apoptosis by sustaining c-Myc expression, inhibiting p27(Kip1) accumulation, and preventing NF-κB suppression after mIgM cross-linking.\",\n      \"method\": \"CD72 pre-ligation followed by mIgM cross-linking, c-Myc protein expression, p27(Kip1) level measurement, NF-κB activity assay\",\n      \"journal\": \"Microbiology and Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined molecular pathway (c-Myc, p27Kip1, NF-κB) with CD72 pre-ligation rescue paradigm, single lab\",\n      \"pmids\": [\"14734859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Semaphorin3A (Sema3A) binds CD72 on B cells as a novel ligand, independent of neuropilin-1. Sema3A binding induces CD72 tyrosine phosphorylation and association of CD72 with SHP-1 and SHP-2. This inhibits STAT-4 and HDAC-1 phosphorylation and induces p38-MAPK and PKC-theta phosphorylation in B cells.\",\n      \"method\": \"Co-immunoprecipitation of Sema3A-CD72 interaction, phosphorylation assays (CD72 tyrosine, SHP-1/2, STAT-4, HDAC-1, p38-MAPK, PKC-theta), neuropilin-1 independence validation, primary B cells from SLE patients\",\n      \"journal\": \"Journal of Autoimmunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP identifying new ligand plus defined signaling pathway, validated in primary B cells, single lab\",\n      \"pmids\": [\"36470209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The alternatively spliced human CD72 isoform lacking exon 8 (CD72Δex8) accumulates in the endoplasmic reticulum and fails to reach the cell surface and fails to regulate BCR signaling, whereas full-length CD72 (CD72fl) is efficiently transported to the cell surface and inhibits BCR signaling.\",\n      \"method\": \"Transfection of CD72fl and CD72Δex8 into mouse cell lines, subcellular fractionation/localization, BCR signaling inhibition assay\",\n      \"journal\": \"BMC Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiment combined with functional BCR signaling assay, single lab\",\n      \"pmids\": [\"23268649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CD72 ligation in the AML cell line Kasumi-1 (expressing mutant KIT) suppresses proliferation and enhances cell death (caspase-3 cleavage), associated with CD72 phosphorylation, CD72-SHP-1 complex formation, and dephosphorylation of Src family kinases and JNK.\",\n      \"method\": \"CD72 ligation with agonistic antibody and recombinant CD100, proliferation assay, caspase-3 cleavage, co-immunoprecipitation of SHP-1, Src and JNK phosphorylation assays\",\n      \"journal\": \"Scientific Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic co-IP plus functional readouts in a defined cell line, single lab\",\n      \"pmids\": [\"24713856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In mouse mast cells, CD72 ligation inhibits KIT-mediated growth, IL-6 production, and chemotaxis via Cbl-b phosphorylation and downregulation of KIT and FcεRIα surface expression. Unlike human mast cells, CD72 in mouse mast cells does not signal through SHP-1 for these effects. IgE-triggered degranulation is also suppressed by CD72 ligation in mouse (but not human) mast cells.\",\n      \"method\": \"CD72 ligation in mouse bone marrow-derived mast cells, Cbl-b phosphorylation assay, KIT and FcεRIα surface expression by flow cytometry, degranulation assay, comparison to human mast cell mechanism\",\n      \"journal\": \"International Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined species-specific mechanism (Cbl-b vs SHP-1), multiple functional readouts, single lab\",\n      \"pmids\": [\"25239131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The CD72c allele is a hypofunctional allele for BCR signal inhibition and functions as a modifier gene that regulates Fas(lpr)-induced lupus-like autoimmune disease. Introduction of the chromosomal interval containing Cd72c caused lupus-like disease on B6/lpr background, while replacement of Cd72c with Cd72b in MRL/lpr congenic mice reduced disease severity.\",\n      \"method\": \"Congenic mouse generation, BCR signaling assays comparing CD72c vs CD72b, disease severity assessment (autoantibodies, CD4⁻CD8⁻ T cells)\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis using congenic strains plus BCR signaling functional comparison of alleles, multiple disease phenotype readouts\",\n      \"pmids\": [\"23616572\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Soluble CD72 (sCD72) binds to CD100 on the surface of T cells and enters the cytoplasm, suppressing T cell adaptive immune functions (reducing CD4+IFN-γ+, CD8+Perforin+, CD8+GZMB+, CD8+FASL+ populations and increasing CD4+TNF-α+ population) in a sepsis model.\",\n      \"method\": \"Recombinant sCD72 injection in CLP sepsis mouse model, flow cytometry of T cell subsets, confocal microscopy showing sCD72 entering T cell cytoplasm, CRISPR/Cas9 CD72-KO mice\",\n      \"journal\": \"International Immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO plus recombinant protein injection with defined cellular phenotypes, single lab, novel mechanism\",\n      \"pmids\": [\"39793226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Soluble CD72 (sCD72) interacts with CD6 on activated CD4+ T cells (identified by mass spectrometry and co-immunoprecipitation) and increases pro-inflammatory cytokines (IL-17A, IFN-γ) and T cell proliferation, activating the SLP-76-AKT-mTOR pathway.\",\n      \"method\": \"Mass spectrometry, co-immunoprecipitation, flow cytometry for cytokine secretion, phosphorylation assay (SLP-76, AKT, mTOR), CFSE proliferation assay\",\n      \"journal\": \"Frontiers in Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mass spectrometry plus co-IP for receptor identification, multiple functional assays, single lab\",\n      \"pmids\": [\"39026665\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CD72 is a type II transmembrane C-type lectin expressed on B cells (and also NK cells and mast cells) that functions primarily as an inhibitory co-receptor: its cytoplasmic ITIM1 recruits SHP-1 upon BCR-induced tyrosine phosphorylation to suppress BCR-mediated ERK activation, Ca²⁺ mobilization, and downstream signaling (NF-AT, NF-κB, MAPK, PI3K/Akt), while ITIM2 recruits Grb2 (and indirectly BLNK) to attenuate this negative signal; its natural ligand CD100/Sema4D induces tyrosine dephosphorylation of CD72 and SHP-1 dissociation, thereby relieving inhibition; CD72 also binds CD5 on T cells (mediating T-B communication), recognizes the lupus self-antigen Sm/RNP through its extracellular C-type lectin-like domain to specifically suppress TLR7-driven autoimmune B cell responses, and can recruit CD19 and activate PI3K to deliver positive signals; the CD72c hypofunctional allele, with altered charge in the membrane-distal extracellular domain, reduces Sm/RNP binding and is a modifier of lupus susceptibility.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CD72 is a type II transmembrane C-type lectin-like receptor that serves as a tunable inhibitory co-receptor governing B cell development and activation [#14, #4]. Its founding topology places the C-type lectin-like domain extracellularly with an inverted membrane orientation lacking an N-terminal signal peptide, defining it within a receptor superfamily including the asialoglycoprotein receptor and CD23 [#14]. The cytoplasmic tail carries two ITIMs: tyrosine-phosphorylated ITIM1 recruits the phosphatase SHP-1 to deliver a strong negative signal, while ITIM2 recruits Grb2 (and an associated BLNK-containing complex) that moderates the SHP-1 signal [#2, #8, #10]. BCR cross-linking drives CD72 tyrosine phosphorylation and SHP-1 association, and CD72 is itself an in vivo SHP-1 substrate whose phosphorylation correlates with BCR-induced growth arrest and apoptosis [#2, #3]. Through this ITIM/SHP-1 axis CD72 dampens BCR-induced ERK and Ca\\u00b2\\u207a mobilization, with downstream suppression of NF-AT, NF-\\u03baB, MAPK and PI3K/Akt signaling; an intact ITIM is required for inhibition [#5, #18]. Genetic loss of CD72 in mice perturbs B cell development and produces hyperproliferative, Ca\\u00b2\\u207a-hyperresponsive B cells, and in antigen-specific anergic settings CD72-deficient B cells inappropriately survive and aged mice develop lupus-like autoimmunity, the latter linked to physical association with and regulation of Cbl-b [#4, #12]. The receptor's extracellular CTLD recognizes the RNA-containing lupus self-antigen Sm/RNP to specifically restrain TLR7-driven B cell responses; the hypofunctional CD72c allele shows altered charge at the ligand-binding site, weaker Sm/RNP binding, and acts as a modifier of lupus susceptibility [#13, #27]. CD72 binding partners include CD5 on T cells and the semaphorin CD100/Sema4D, whose engagement induces CD72 dephosphorylation and SHP-1 dissociation to switch off inhibitory signaling and set BCR signal sensitivity [#0, #1, #11]. Beyond its inhibitory role, CD72 ligation can deliver positive, Syk-independent signals by activating Lyn, Blk and Btk and recruiting CD19-associated PI3-kinase [#6, #7]. CD72 functions analogously as an inhibitory receptor on NK cells and mast cells [#15, #16].\",\n  \"teleology\": [\n    {\n      \"year\": 1987,\n      \"claim\": \"Established that engaging CD72 (Lyb-2) triggers an intrinsic signaling response, distinct from cytokine pathways, indicating it is not merely a passive surface marker.\",\n      \"evidence\": \"Anti-Lyb-2 antibody-induced phosphatidylinositol hydrolysis assay in murine B cells with BSF-1 competition controls\",\n      \"pmids\": [\"3499987\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No molecular identity of the signaling intermediates\", \"Allele specificity unexplained at the structural level\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Defined the molecular architecture of CD72, resolving that it is an inverted type II C-type lectin-like receptor rather than a conventional receptor.\",\n      \"evidence\": \"cDNA sequencing and predicted topology analysis placing it in a C-type lectin superfamily with the asialoglycoprotein receptor and CD23\",\n      \"pmids\": [\"2645579\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No ligand identified at this stage\", \"No functional consequence of the lectin fold tested\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Identified the first CD72 binding partner, CD5 on T cells, establishing CD72 as a mediator of T-B cell communication.\",\n      \"evidence\": \"Biotin-labeled CD5 probe binding, antibody blocking, and gain-of-function CD72 transfection into non-B cells\",\n      \"pmids\": [\"1711157\", \"1371783\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling consequence of CD5-CD72 binding not defined\", \"Affinity and stoichiometry not quantified\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Resolved the proximal signaling machinery, showing CD72's cytoplasmic ITIM recruits SHP-1 upon BCR-induced phosphorylation and that CD72 is an in vivo SHP-1 substrate whose phosphorylation tracks with growth arrest/apoptosis; also mapped both positive (Lyn/Blk/Btk, CD19-PI3K) and negative arms.\",\n      \"evidence\": \"ITIM phosphopeptide pull-down, co-IP from BCR-stimulated B cells, kinase activity assays, xid (Btk-deficient) B cells, and reciprocal CD19/CD72 co-IP\",\n      \"pmids\": [\"9590210\", \"9740800\", \"9531290\", \"9808169\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a single receptor switches between positive and negative outputs unresolved\", \"CD19-CD72 association is transient and from a single lab (#7)\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identified the transcriptional basis of B-cell-restricted CD72 expression, linking lineage-specific gene control to PU.1.\",\n      \"evidence\": \"DNase I footprinting, EMSA, and reporter mutagenesis of the PU.1 site in B vs non-B cells\",\n      \"pmids\": [\"9498769\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other regulatory inputs to CD72 expression not mapped\", \"No link between expression level and signaling output\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstrated through genetics that CD72 is a nonredundant negative regulator of B cell activation and development in vivo, not merely an in vitro signaling artifact.\",\n      \"evidence\": \"CD72-knockout mice with B cell subset flow cytometry, proliferation, and intracellular Ca\\u00b2\\u207a measurements\",\n      \"pmids\": [\"10549631\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not connect phenotype to a physiological ligand\", \"Developmental versus activation roles not mechanistically separated\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified CD100/Sema4D as the physiological ligand and defined the regulatory logic: CD100 binding dephosphorylates CD72 and dissociates SHP-1, switching off inhibition; ITIM mutagenesis confirmed the ITIM is required for negative signaling; BLNK was placed in the CD72/SHP-1/Grb2 complex.\",\n      \"evidence\": \"Expression cloning, affinity measurement, dephosphorylation and SHP-1 dissociation assays, ITIM-mutant transfection with ERK/Ca\\u00b2\\u207a readouts, and quaternary complex co-IP\",\n      \"pmids\": [\"11114375\", \"10640734\", \"10820378\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"BLNK complex shown by single-lab co-IP (#8)\", \"How CD100 engagement mechanistically drives CD72 dephosphorylation not resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Dissected the two ITIMs functionally and established CD100 sets BCR signal sensitivity in vivo, with CD100 loss causing constitutive SHP-1 association, hyporesponsiveness, and aging autoimmunity.\",\n      \"evidence\": \"ITIM Tyr-to-Phe mutant panels with growth-inhibition readout and CD100-knockout mice with CD72-BCR co-IP and autoantibody measurement\",\n      \"pmids\": [\"15816000\", \"16113236\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ITIM2/Grb2 moderation mechanism (#10) from single lab\", \"Structural basis of constitutive CD72-BCR association unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Connected CD72 directly to tolerance and autoimmunity, showing it enforces anergy by limiting antigen-induced signaling and by regulating Cbl-b, with its loss producing lupus-like disease.\",\n      \"evidence\": \"CD72-knockout HEL-BCR transgenic mice, Ca\\u00b2\\u207a/NF-\\u03baB/NFAT/MAPK/Akt assays, and Cbl-b co-IP\",\n      \"pmids\": [\"18821699\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which CD72 regulates Cbl-b not detailed\", \"Did not identify the self-antigen recognized\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established the CD72c allele as a hypofunctional lupus modifier gene through genetic epistasis, linking allelic variation in CD72 to autoimmune disease severity.\",\n      \"evidence\": \"Congenic mouse strains with allele swaps and BCR signaling comparison plus disease scoring\",\n      \"pmids\": [\"23616572\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural/biochemical basis of CD72c hypofunction not yet defined at this step\", \"Human relevance of the murine allele not addressed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Provided the structural and mechanistic explanation for CD72's autoimmune specificity, showing the extracellular CTLD directly binds Sm/RNP to suppress TLR7-driven responses and that CD72c bears charge alterations weakening this binding.\",\n      \"evidence\": \"CTLD-Sm/RNP binding assay, TLR7-dependent B cell inhibition assay, and X-ray crystallography of the CD72c CTLD\",\n      \"pmids\": [\"27810925\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-crystal structure of CTLD with Sm/RNP not solved\", \"How CTLD ligand recognition couples to cytoplasmic ITIM signaling unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Extended CD72 inhibitory function beyond B cells to NK cells and mast cells, revealing both shared (SHP-1) and species-divergent (Cbl-b) effector usage.\",\n      \"evidence\": \"Ectopic CD72 expression with IFN-\\u03b3 readout in NK line, and CD72 ligation in human and mouse mast cells with SHP-1/Cbl-b co-IP and functional assays\",\n      \"pmids\": [\"19197938\", \"20100931\", \"25239131\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic basis of human/mouse mast cell divergence unexplained\", \"NK and mast cell findings each from single labs\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified new ligands and a soluble form of CD72 acting on T cells, indicating CD72 functions beyond a membrane-bound B cell receptor.\",\n      \"evidence\": \"Sema3A co-IP and signaling in SLE B cells; soluble CD72 binding CD100 and CD6 on T cells with phenotypic and pathway readouts in sepsis and inflammation models\",\n      \"pmids\": [\"36470209\", \"39793226\", \"39026665\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Soluble CD72 mechanism (cytoplasmic entry, CD6/CD100 engagement) from single labs\", \"Physiological source and abundance of soluble CD72 not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How extracellular CTLD ligand recognition (Sm/RNP, CD100, CD5, Sema3A) is structurally transmitted to the dual-ITIM cytoplasmic module to bias positive versus negative signaling remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of CD72 ectodomain bound to any ligand\", \"No reconstituted model coupling ligand binding to ITIM phosphorylation state\", \"Determinants selecting SHP-1 inhibition versus Lyn/Btk/CD19-PI3K activation undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 5, 10, 18]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 0, 13]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2, 8, 12]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [1, 0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [14, 24]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 5, 18, 12]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 5, 1, 7]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [12, 13, 27]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"SHP-1\", \"Grb2\", \"CD100\", \"CD5\", \"CD19\", \"BLNK\", \"Cbl-b\", \"Btk\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":10,"faith_total":10,"faith_pct":100.0}}